Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
about
Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceWill Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World DataUtility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antiviralsHIV cure strategies: how good must they be to improve on current antiretroviral therapy?Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysisPredictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysisCost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United StatesCost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study.Clinical impact of treatment timing for chronic hepatitis C infection: a decision modelCost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the NetherlandsEstimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China.Cost-effectiveness thresholds: pros and cons.A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection.Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service.Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.Treating hepatitis C in the elderly: the future is near?Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection.Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals.Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy.Why do I treat my patients with mild hepatitis C?Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies.Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals.Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease.Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection.Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study.Fair prices for new direct-acting antiviral agents (DAAs) to make treatment for all affordable.Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study.Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease.Sofosbuvir vs. Combination of Pegylated Interferon and Ribavirin; How Much Shall Pay for Iranian Patients?European Association for the Study of the Liver Hepatocellular Carcinoma summit 2014: old questions, new (or few) answers?Editorial: can we afford the new direct-acting antivirals for treatment of genotype 1 hepatitis C?Sofosbuvir: A Nucleotide NS5B Inhibitor for the Treatment of Chronic Hepatitis C Infection.
P2860
Q28072257-A0E341EC-2589-4970-AFCA-209771A1913CQ28550101-B8149104-9824-4BE7-AB67-55B35D20A109Q33423299-98CEC05D-2C1E-49F2-A74F-58D83CCB28CCQ34163405-6481DF22-25B6-42BF-AF15-7187CDEC628BQ34514601-A9CBCE78-DD2A-4415-836C-6FBB93F5F611Q35037688-6577CB5A-3607-4C42-9202-6AB204ECE6ACQ35370579-EED47AE1-3C8B-4C34-8B89-499CC2164F9EQ35606843-3D03B285-DDD0-4FBA-B2CE-D8C1BBFCB3E4Q35619161-8930F30A-24B5-4385-88C8-B3C4C22C967AQ35736293-FE5B4D2B-03E1-4B56-BBE6-C1587D015D96Q35776195-B87F9170-9E1E-4866-9BE5-69D27D91FEBFQ35889164-7A66EF27-2576-412A-8EE0-8C539CFF5A75Q36155257-EDE669AF-2098-45CC-A14F-65F232EBF18EQ36336005-C13B4100-9681-48EA-B9A4-29703F927F0BQ37498173-6717F728-4286-4A0E-9CEE-FA4393A8997DQ37629097-9CABB2CE-9A5B-4BD5-A71E-AE2E7109946DQ37682673-E3746203-C75F-4524-84CF-67600895DFF3Q38205737-3AEC7C5A-9427-411F-BAB1-0DF3823E26AFQ38243001-3D0B5B2E-C96F-4616-A63C-87A734F280FAQ38249065-B3A7DCA1-625E-4195-87AD-74247BD78685Q38445623-F228C197-3ABC-41A8-88D0-9D6B38100CFEQ38470584-5DF247F0-590F-457D-BD8D-90AF1CA76CEFQ38566022-F3ED4EDA-D1C6-4EFB-9885-015AC42D9D82Q38685564-61FD43D9-5833-4A77-941A-7FC98BCFFA25Q38691333-2080BA4A-910D-400A-840A-3A09F0A09A8BQ38755073-33FDA1BD-C63A-45ED-8BCC-03CF290CD851Q38800572-547155E4-C44C-4046-BA6D-C314B9EE1F0AQ38846558-49D9D011-A69B-49ED-8B55-0E04250A532BQ38932103-62729426-9D2A-4641-A9DA-F8F324AF99DFQ40562865-1D8BE7F1-0ECD-4D93-9AA5-A30BF65CBBC3Q40597591-489A00D3-FE14-4508-A900-FEC642A0F44DQ40677384-A0D3025C-7954-4199-BC84-C4B99C6E03C4Q40690948-15C0A836-5E21-40AE-929E-53D1359F4F12Q41612169-0DDA4DFC-2925-4A21-B945-741F53896658Q41711786-12D53EF2-A16B-4A62-A74F-CF404A391D39Q42048758-D05FFFEB-A7CB-4594-82FA-B9EF45F5921BQ43095281-8915A9E6-C120-4F4F-A551-A1692F059510Q48760305-42CFF816-F4A5-4CF5-B55C-03C585A33510Q50280206-FEF01DF7-4DCE-4C93-BDEB-741797089C34Q50283110-81335EA9-6278-49BF-BD1F-F88208AE4345
P2860
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Cost-effectiveness of sofosbuv ...... enotype 1 chronic hepatitis C.
@en
Cost-effectiveness of sofosbuv ...... enotype 1 chronic hepatitis C.
@nl
type
label
Cost-effectiveness of sofosbuv ...... enotype 1 chronic hepatitis C.
@en
Cost-effectiveness of sofosbuv ...... enotype 1 chronic hepatitis C.
@nl
prefLabel
Cost-effectiveness of sofosbuv ...... enotype 1 chronic hepatitis C.
@en
Cost-effectiveness of sofosbuv ...... enotype 1 chronic hepatitis C.
@nl
P2093
P2860
P50
P356
P1433
P1476
Cost-effectiveness of sofosbuv ...... enotype 1 chronic hepatitis C.
@en
P2093
Antonio Gasbarrini
Calogero Cammà
Marco Enea
WEF Study Group
P2860
P304
P356
10.1002/HEP.27010
P407
P577
2014-04-01T00:00:00Z